A Multi-national, Open-label, Dose Escalation Phase I/II study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types

Trial Profile

A Multi-national, Open-label, Dose Escalation Phase I/II study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs NKR 2 (Primary)
  • Indications Acute myeloid leukaemia; Advanced breast cancer; Bladder cancer; Colorectal cancer; Haematological malignancies; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms THINK
  • Sponsors Celyad
  • Most Recent Events

    • 03 Oct 2017 According to a Celyad media release, 14 patients have been dosed in the trial.
    • 03 Oct 2017 Results published in a Celyad media release.
    • 12 Sep 2017 The trial has completed enrollment in its first cohort among solid indications as per trial design presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top